Regulatory Update United States European Union United Kingdom Canada Brazil Japan China South Korea Switzerland International Other Regulatory Quality Clinical Post-Market Manufacturing & Supply Chain Software, SaMD & Cybersecurity IVD AI

Syneris Weekly Briefing

Global Regulatory Intelligence Review

Medical devices · IVDs · SaMD  |  Published 9 Nov 2026 · Review window 30 Oct – 9 Nov 2026

15developments tracked
2action required
8for RA review
5informational

Top stories this week

About this edition

Every development in this edition has been confirmed against the issuing regulator's own publication, and links go directly to those primary sources.

  • Action required — the change is likely to require regulatory or compliance action, such as a registration, submission, notified-body application or QMS update.
  • Review — the change may be relevant and should be assessed by regulatory affairs for applicability to specific products or markets.
  • Informational — useful intelligence; no immediate action identified.

Status: NEW / REVISED / PROPOSED / UPCOMING / CLARIFICATION. Impact ratings are a general guide; applicability depends on your products and markets.

This week at a glance

#JurisdictionDevelopmentScopeStatusImpact
1EUEUDAMED: devices already on the market must be registered by 28 Nov 2026MD + IVDUPCOMINGAction required
2CanadaMDEL Phase 2 takes effect 1 Dec 2026, with revised inspection guidance GUI-0064MD + IVDUPCOMINGAction required
3USFinal guidance on validating IVDs for emerging pathogens in a declared emergencyIVDNEWReview
4USAI-assisted digital cervical cytology systems classified into Class II (21 CFR 864.3900)IVD / AINEWReview
5South KoreaMFDS revises its device cybersecurity review guidelineMD / SaMDREVISEDReview
6ChinaNMPA issues revised GMP inspection guidelines for IVD reagents, sterile and implantable devicesMD + IVDNEWReview
7EUMDCG 2026-6: clinical evidence for orphan IVDsIVDNEWReview
8CanadaRevised List of Recognized Standards in effect from 2 Nov 2026MD + IVDREVISEDReview
9JapanMHLW sets out how IVD performance re-evaluation and reporting will work from 20 May 2027IVDCLARIFICATIONReview
10JapanPMDA device web application platform still offline; no restart dateMD + IVDCLARIFICATIONReview
11JapanDevice class designations amended: two new generic names, two definitions changedMDREVISEDInfo
12USThree further De Novo classifications, one for prognostic softwareMD / SaMDNEWInfo
13USFinal CBER guidance on hepatitis B testing of blood donationsIVDNEWInfo
14USFDA discussion paper on robotic devices with autonomy or remote teleoperationMDPROPOSEDInfo
15ChinaDraft guide on device vigilance in hospitals (comments to 25 Nov)MD + IVDPROPOSEDInfo

Significant new developments

FDA finalises its emerging-pathogen IVD validation guidance

US · IVD · New · Review

FDA has issued the final version of "Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency", dated November 2026, replacing the January 2025 draft under docket FDA-2024-D-2707 (FDA). The notice of availability is scheduled for the 10 November Federal Register (Federal Register).

The guidance and its template set out the validation data FDA expects in a pre-EUA, an EUA request, or for a test offered under an emergency enforcement-discretion policy. Developers that keep emergency-response assay platforms should compare their preparedness protocols with the final template.

↑ Back to this week at a glance

AI-assisted cervical cytology gets its own Class II regulation

US · IVD / AI · New · Review

A final order published on 5 November codifies 21 CFR 864.3900, the digital cervical cytology slide imaging system with an AI algorithm, in Class II with special controls (Federal Register). The device is a prescription IVD that selects and presents areas of interest on digital images of Pap test slides to help the reader reach a cytology diagnosis. The classification has applied since the De Novo grant on 31 January 2024.

Developers of cervical-screening software and image-based tests can now use this device type as a predicate, and should map the special controls, including labeling under 21 CFR 809.10(b), against their submissions.

↑ Back to this week at a glance

South Korea tightens its device cybersecurity review criteria

South Korea · MD / SaMD · Revised · Review

MFDS revised its cybersecurity approval and review guideline for medical devices on 30 October (guideline 0995-06) (MFDS). The revision changes requirement items on changing authentication information, password strength set according to product characteristics, input-validation checks and evidence for error handling.

MFDS briefed industry on 28 October and will run online training on 26 November (MFDS press release). Manufacturers of connected devices and software registered in Korea should check their cybersecurity files against the revised items.

↑ Back to this week at a glance

China: new GMP inspection guidelines for IVD reagents and other high-risk devices

China · MD + IVD · New · Review

NMPA notice 国药监械管〔2026〕16号 issues revised GMP inspection guidelines for sterile devices, implantable devices, IVD reagents and custom dentures. They have applied since 1 November 2026 and replace the 2015 and 2016 on-site inspection guidelines; licensing and post-market inspections are now judged against them (CFDI, reposting the NMPA notice).

They sit alongside the revised device GMP and general inspection guideline, also in force from 1 November (NMPA). Companies with IVD or sterile production sites in China, including contract manufacturers, should check their sites against the new IVD and sterile texts.

↑ Back to this week at a glance

EU guidance on clinical evidence for orphan IVDs

EU · IVD · New · Review

The MDCG has published MDCG 2026-6 on clinical evidence for orphan IVDs, meaning tests for conditions affecting no more than 12,000 people a year in the EU (European Commission). It explains when limited clinical performance data can be justified and how expert panels are involved. Manufacturers of rare-disease IVDs should read it before planning their IVDR performance evaluation.

↑ Back to this week at a glance

Updates to existing requirements

Canada revises its List of Recognized Standards

Canada · MD + IVD · Revised · Review

Health Canada's revised list took effect on 2 November 2026 (Health Canada). New entries include CLSI EP35 on specimen-type equivalence for IVDs, IEC 80601-2-26, -2-49 and -2-77, ISO 17665 and ISO 18562-1 and -2. CLSI MM12 and MM16, IEC 60601-2-26 and -2-49, ISO 17665-1 and ISO 8359 are among the standards removed, and recognition of CLSI EP25, IEC 60601-2-24 and ISO 10993-1 has been updated.

No transition period is stated. Manufacturers citing removed or superseded editions in Canadian declarations of conformity should update them.

↑ Back to this week at a glance

Japan details IVD performance re-evaluation ahead of May 2027

Japan · IVD · Clarification · Review

An MHLW implementation notice dated 30 October sets out how the amended PMD Act provisions taking effect on 20 May 2027 will work (MHLW). IVD performance re-evaluation will mirror the drug re-evaluation system, with reliability standards for application data and products in scope announced in the Official Gazette. IVDs designated by the Minister will need ongoing information gathering and periodic reports, submitted through PMDA within two months of each reporting period.

The notice also requires registered certification bodies to give six months' notice, instead of two weeks, before suspending certification work. MHLW says further operational details will follow.

↑ Back to this week at a glance

PMDA platform still offline

Japan · MD + IVD · Clarification · Review

PMDA's notice on the suspension of its Medical Device Web Application Platform was posted on 29 October; the service is still suspended and no restart date has been set (PMDA). Applications and notifications should continue to go through MHLW's FD application software, and PMDA has yet to announce how documents in pending files can be replaced.

↑ Back to this week at a glance

Japan amends device class designations

Japan · MD · Revised · Informational

MHLW notice 医薬発1105第4号 of 5 November adds generic names for an intraocular implantable drug-delivery system (Class IV) and a household nitric-oxide circulation-promotion garment (Class I), and amends the definitions of central circulatory microcatheters and body-temperature regulation systems (MHLW). No IVD categories change.

↑ Back to this week at a glance

US: three more De Novo classifications

US · MD / SaMD · New · Informational

Final orders published on 5 and 6 November create device types for prognostic assessment software for mild cognitive impairment (21 CFR 882.1454), a wearable vibration device for orthopedic use (21 CFR 888.5895) and an external mechanical stimulator for ear, nose and throat use (21 CFR 874.6010). None are IVDs.

↑ Back to this week at a glance

US: final guidance on hepatitis B testing of blood donations

US · IVD · New · Informational

CBER's final guidance on reducing the risk of transfusion-transmitted hepatitis B was announced on 3 November (Federal Register; FDA). Blood establishments that test with HBV nucleic acid tests and anti-HBc no longer need to test for HBsAg, but Source Plasma testing stays as it is. Makers of blood-screening assays should expect demand to shift.

↑ Back to this week at a glance

On the horizon

FDA asks for views on autonomous and remotely operated robotic devices

US · MD · Proposed · Informational

CDRH has published a discussion paper on benefit-risk for robotic devices with autonomous or remote teleoperation capabilities, with comments due by 5 January 2027 under docket FDA-2026-N-13135 (FDA). A public workshop follows on 2–3 December (FDA workshop).

↑ Back to this week at a glance

China consults on device vigilance in hospitals

China · MD + IVD · Proposed · Informational

NMPA's Center for Drug Reevaluation has released a draft guide on medical device vigilance work in medical institutions, with comments due by 25 November (CDR). It covers the user-facility side of vigilance and adds nothing new for manufacturers yet.

↑ Back to this week at a glance

Clarifications worth noting

EU — EUDAMED registration. Devices already on the market must be registered in EUDAMED by 28 November 2026 (Commission timeline).

Canada — MDEL Phase 2 and inspections from 1 December. The MDEL Phase 2 amendments, the online FRM-0292 and the new GUI-0016 take effect on 1 December 2026 (Health Canada bulletin). A revised version of GUI-0064, which describes how Health Canada inspects medical device establishments, takes effect the same day and replaces version 7 (GUI-0064).

US — QMSR FAQ. FDA's QMSR FAQ page was updated on 5 November with a new contact address (AskOICE@fda.hhs.gov); the policy is unchanged (FDA).

Japan — PMDA and AI. PMDA has published early basic principles for its own use of AI in regulatory work. They set no new requirements for products (PMDA).

Standards changes

Canada — recognized standards. The revised List of Recognized Standards took effect on 2 November 2026; see the item above (Health Canada).

EU — Battery Regulation. Delegated Regulation (EU) 2026/1770 applies from 11 November 2026 and keeps the derogation for IVDs (EUR-Lex). No new MDR/IVDR harmonised-standards decision and no new FDA recognized-standards list were published this week.

Upcoming implementation deadlines

Next 30 days (9 Nov – 9 Dec 2026)

DateJurisdictionItemScopeImpact
10 Nov 2026Switzerlandswissdamed webinarMD + IVDInfo
11 Nov 2026EUDelegated Reg. (EU) 2026/1770 applies (batteries; IVD derogation)MD + IVDInfo
16 Nov 2026South KoreaComments close: MFDS IVD regulation amendment (MFDS)IVDReview
17 Nov 2026USComments close: PMA eSTAR draft guidanceMD + IVDInfo
19 Nov 2026USMicrobiology Devices Panel (pathogen-agnostic sequencing)IVDReview
23 Nov 2026USComments close: ASCA information collectionMD + IVDInfo
24 Nov 2026USComments close: RASD draft guidanceMDReview
25 Nov 2026ChinaComments close: draft hospital vigilance guideMD + IVDInfo
26 Nov 2026South KoreaMFDS online training on the revised cybersecurity guidelineMD / SaMDInfo
28 Nov 2026EUEUDAMED registration of devices already on the marketMD + IVDAction required
30 Nov 2026USComments close: CDRH FY2027 guidance listsMD + IVDInfo
1 Dec 2026CanadaMDEL Phase 2 in force; online FRM-0292, GUI-0016 and GUI-0064 effectiveMD + IVDAction required
2–3 Dec 2026USFDA workshop on robotic devices with autonomy or teleoperationMDInfo
3 Dec 2026IMDRFN52 Ed.3 labeling consultation closes (IMDRF)MD + IVDReview

Next 90 days (to 7 Feb 2027)

DateJurisdictionItemScopeImpact
10 Dec 2026South KoreaMedical Devices Act amendment (Act 21775) in forceMDReview
11 Dec 2026BrazilSandbox CP 1.427/2026 closesHorizontalInfo
14 Dec 2026EUIndicative plenary date, MDR/IVDR revision (OEIL)MD + IVDReview
Dec 2026EUSSCP/SSP upload opens in EUDAMED (planned)MD + IVDReview
Dec 2026UKMHRA draft PCCP guidance plannedSaMD/AIReview
22 Dec 2026USComments close: product jurisdiction / export certificate information collectionsMD + IVDInfo
26 Dec 2026USCOVID-19 device EUAs end, including SARS-CoV-2 testsIVDAction required
28 Dec 2026USComments close: IDE eSTAR draft guidanceMD + IVDReview
31 Dec 2026SwitzerlandEnd of swissdamed device registration transitionMD + IVDReview
31 Dec 2026SingaporeHSA Registration Support Initiative window endsMD + IVDInfo
5 Jan 2027USComments close: robotic devices discussion paperMDInfo
28 Jan 2027USComments close: essential drug delivery draft guidanceMDReview
28 Jan 2027BrazilCP 1.420–1.423/2026 closeMDInfo

Next 180 days (to 8 May 2027)

DateJurisdictionItemScopeImpact
25 Feb 2027EUImplementing Reg. (EU) 2026/977 notified-body maximum timelines apply (EUR-Lex)MD + IVDReview
17 Mar 2027JapanComments close: PMDA generative AI review pointsSaMD/AIReview
27 Mar 2027EUSSCP/SSP upload for devices already on the market (MDCG 2026-4 rev.1)MD + IVDReview

Next 365 days (to 9 Nov 2027)

DateJurisdictionItemScopeImpact
20 May 2027JapanPMD Act amendments in force, including IVD performance re-evaluation and reportingIVDReview
26 May 2027EUIVDR legacy Class B / sterile Class A: notified-body application deadline; UDI carrier required on Class A IVD labelsIVDAction required
17 Jun 2027CanadaGUI-0137 v4 shortage reporting guidance effectiveMD + IVDReview
26 Sep 2027EUIVDR legacy Class B / sterile Class A: notified-body written agreement deadlineIVDAction required

EU IVDR transition dates: EUR-Lex – Regulation (EU) 2024/1860; IVDR UDI dates: EUR-Lex – Regulation (EU) 2017/746, Art. 113.

About this briefing

Compiled from primary regulatory sources (national authorities, official legislation and gazettes, European Commission, MDCG, FDA and the Federal Register). Secondary sources are used only for discovery; developments that could not be confirmed from a primary source are not published. Requirements in one jurisdiction should not be assumed to apply in another. This briefing is for information only and is not legal or regulatory advice; confirm applicability with your regulatory affairs team before acting.

Previous
Previous

Medical Device Design Change Checklist: From Request to Closure

Next
Next

Medical Device NPI Checklist: A Gate-by-Gate Launch Playbook